Date: 04-Nov-2019

China okays sale of first home-grown Alzheimer's drug

China has approved the first home-grown drug for the treatment of "mild to moderate Alzheimer's disease (AD) and improving cognitive function", according to its developers. The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer's disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences. Oligomannate will provide a new treatment option to fight Alzheimer's disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday.